Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 450

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1A
Chunk 450
---
 reporting, or if we are unable to comply with the requirements
of Section 404 in a timely manner or assert that our internal control over financial reporting is effective, or if our independent registered
public accounting firm is unable to express an opinion as to the effectiveness of our internal control over financial reporting when
required, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our securities
could be negatively affected, and we could become subject to investigations by the stock exchange on which our securities are listed,
the SEC, or other regulatory authorities, which could require additional financial and management resources.

We
are a “smaller reporting company” and, even if we no longer qualify as an emerging growth company, we may still be subject
to reduced reporting requirements.

Additionally,
we are a “smaller reporting company” as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take
advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements.
We will remain a smaller reporting company until the last day of any fiscal year for so long as either: (i) the market value of our shares
of common stock held by non-affiliates does not equal or exceed $250 million as of the prior June 30th; or (ii) our annual
revenues did not equal or exceed $100 million during such completed fiscal year. To the extent we take advantage of such reduced disclosure
obligations, it may also make the comparison of our financial statements with other public companies difficult or impossible.

If
we fail to maintain compliance with Nasdaq Listing Rules, our shares may be delisted from Nasdaq, which would result in a limited trading
market for our shares and make obtaining future debt or equity financing more difficult for the Company.

Our
common stock is listed on the Nasdaq Capital Market under the symbol “TELO”. However, there is no assurance that we will
be able to continue to maintain our compliance with the Nasdaq continued listing requirements. If we fail to do so, our securities may
be de-listed and cease trading on Nasdaq. As a result, selling our securities could be more difficult because smaller quantities of shares
or warrants would likely be bought and sold, transactions could be delayed, and security analysts’ coverage of us may be reduced.
In addition, in the event our securities are delisted, broker-dealers would face certain regulatory requirements which may discourage
them